Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and ...

Cidara Therapeutics, a US biotech leveraging its Cloudbreak platform for next‑generation antivirals, saw its stock more than ...

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current ...

Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo End of Phase 2 meeting request has ...

Shares of San Diego-based Cidara Therapeutics Inc. (NASDAQ:CDTX) were trading at $40.41, up $19.39, or 92%, on positive top-line results from its randomized, double-blind, placebo-controlled phase IIb ...

The adjusted incidence of transmission of influenza virus by day 5 that resulted in symptoms was 5.8% with baloxavir and 7.6% with placebo, but this difference was not significant (adjusted OR 0. ...

Neuraminidase is a rational target for influenza inhibition, and the search for neuraminidase inhibitors has been intensified. Mimosine, a nonprotein amino acid, was for the first time identified as a ...